Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
1	19/LO/0272	255069	A randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND)	28/06/2019	16/10/2019	13/06/2019	22/10/2019	24/10/2019	30/10/2019	18/11/2019	Please select	
2	19/NW/0482	269475	A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del	15/10/2019	15/10/2019	20/09/2019	16/10/2019	21/10/2019	21/10/2019	07/11/2019	Please select	
3	19/EM/0258	266702	A randomised controlled trial of full milk feeds versus intravenous fluids with gradual feeding for preterm infants (30-33 weeks gestational age)	27/09/2019	01/10/2019	13/09/2019	01/10/2019	03/10/2019	04/10/2019	27/01/2020	Neither	This study was difficult to recruit to, due to the strict patient eligibility criteria
4	19/ES/0071	249602	Language and auditory processing in children with cleft palate: a description of the disorder and its relationship to speech outcomes	11/10/2019	11/10/2019	23/07/2019	16/10/2019	23/10/2019	23/10/2019	09/11/2019	Please select	
5	18/WM/0257	211232	NOSTRA-Feasibility Study: A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies	20/09/2019	04/10/2019	15/08/2019	07/10/2019	16/10/2019	16/10/2019		Sponsor	The team are waiting for a protocol change in the permissible chemotherapy regime before starting to recruit
6	19/SC/0034	254823	A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	25/09/2019	03/10/2019	29/04/2019	10/10/2019	15/10/2019	15/10/2019	19/11/2019	Please select	
7	19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks	30/10/2019	30/10/2019	24/09/2019	20/11/2019	25/11/2019	27/11/2019	12/02/2020	Neither	There was delays locating the first patients that fit the inclusion/exclusion criteria. The study requirement was they have had a standard of CT scan within the one year
8	19/LO/0153	259690	A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or II	20/09/2019	24/10/2019	29/03/2019	05/11/2019	08/11/2019	12/11/2019	27/02/2020	Sponsor	Although confirmation of C&C was granted in November, there was a delay with the sponsor providing their green light which I think was in part due to a change of CRA at the same time so the study wasn't activated locally until 15th January, 2020
9	19/SC/0256	263749	A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients	11/11/2019	13/11/2019	20/09/2019	19/11/2019	25/11/2019	26/11/2019		Sponsor	The study opened without the sponsor having gained approval to use a patient letter, specifically for PIC sites to send out to potential participants. Recruitment to this study is very much dependent on PIC sites and the approval to implement the amendment was only received on the 04/08/2020

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
10	19/EE/0135	252796	A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan with HM30181A Monotherapy in Patients with Advanced Malignancies	06/11/2019	18/11/2019	27/06/2019	18/11/2019	19/11/2019	20/11/2019	03/03/2020	Neither	This is a dose finding study, when we opened the current cohort was full, we got a slot on the next one in February but our patient needed a 28 day washout from a medicine they were on, so this caused another delay
11	19/YH/0067	254066	A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)	17/10/2019	07/11/2019	23/04/2019	04/11/2019	12/11/2019	12/11/2019	21/11/2019	Please select	
12	19/NI/0110	260538	EluNIR Ridaforolimus Eluting Coronary Stent System in patients at high bleeding risk (HBR)– EluNIR HBR study	11/09/2019	13/11/2019	01/08/2019	14/11/2019	20/11/2019	20/11/2019		Sponsor	Due to an issue with the supplier for the study stent which stopped commercialising the stent at the end of February the study had to close early without recruiting a patient
13	19/NS/0124	256842	Peeling of the ILM from the retinal surface with finesse forceps; the PRECISE study	08/11/2019	08/11/2019	11/09/2019	19/11/2019	19/11/2019	19/11/2019	19/12/2019	Please select	
14	19/LO/1035	264950	A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular Psoriasis	01/10/2019	05/11/2019	13/08/2019	06/11/2019	08/11/2019	08/11/2019	27/02/2020	Neither	R&D's confirmation of capacity and capability was issued on 08/11/2019. Sponsor's activation of site was on 11/11/2019. Participants were sought but no eligible participants identified. PI arranged two extra clinics to try and find study patients which resulted in First patient screened on 27/02/2020. First patient was recruited on 10/03/2020.
15	19/NE/0115	255707	An Open Label, Multi-Centre, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence® (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis	22/10/2019	05/11/2019	03/07/2019	01/11/2019	08/11/2019	08/11/2019	02/01/2020	Please select	
16	19/NE/0069	254703	The role of PREVENA vacuum dressings in patients undergoing bilateral mammoplasty surgery	10/12/2019	17/12/2019	22/05/2019	17/12/2019	20/12/2019	20/12/2019	13/02/2020	Please select	
17	18/EM/0255	237130	Proof of Concept Study: Safety and Feasibility Study of Lumen-Apposing Stents (LAMS) in EUS-Guided Biliary Drainage	18/10/2019	28/11/2019	09/10/2018	03/12/2019	03/12/2019	03/12/2019		Neither	No patients have presented to the study team due to the strict eligibility criteria. Sponsor closed the study earlier than expected and no patients were recruited at Newcastle
18	19/YH/0054	258802	A pragmatic, multicentre, randomised controlled trial to assess the clinical and cost effectiveness of negative pressure wound therapy versus usual care for surgical wounds healing by secondary intention (SWHSI 2)	30/04/2019	03/12/2019	05/04/2019	11/12/2019	16/12/2019	17/12/2019	21/01/2020	Please select	
19	18/SC/0628	253656	A two-part, Phase I, open-label, dose-escalation and expansion study to assess the safety, pharmacokinetics and clinical activity of NUC-7738, a nucleotide analogue, in patients with advanced solid tumours or lymphoma	23/05/2019	19/11/2019	24/12/2019	09/12/2019	16/12/2019	17/12/2019		Neither	This study is a phase I dose finding clinical trial, there were no slots available when it first opened and although the team did not close during COVID they slowed recruitment
20	19/NE/0119	257479	Efficacy of physical activity tele-coaching to optimise daily physical activity levels in lung transplant recipients	05/06/2019	18/12/2019	29/05/2019	18/12/2019	18/12/2019	18/12/2019	06/02/2020	Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
21	19/NW/0540	269907	A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis	23/07/2019	13/12/2019	06/11/2019	18/12/2019	23/12/2019	23/12/2019	29/01/2020	Please select	
22	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	30/09/2019	12/12/2019	18/09/2018	13/12/2019	18/12/2019	18/12/2019	22/01/2020	Please select	
23	19/EM/0072	256161	A Long-Term, Randomized, Double-Blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as needed in Response to Symptoms in Symptomatic Adults and Children 4 years of Age or Older with Asthma (MANDALA)	02/08/2019	13/12/2019	21/06/2019	16/12/2019	18/12/2019	19/12/2019	04/02/2020	Please select	
24	18/LO/2045	252053	The 'Radiance II' Pivotal Study. A study of the ReCor Medical Paradise System in Stage II Hypertension.	05/08/2019	17/12/2019	25/01/2019	20/12/2019	20/12/2019	20/12/2019		Neither	No suitable participants were identified who met the inclusion criteria and whom the investigator felt would have the capacity to comply with this complex double blind device trial
25	19/LO/0357	258769	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy.	21/11/2019	27/11/2019	28/05/2019	24/11/2019	03/12/2019	05/12/2019		Sponsor	The team received the Green Light from the Trust in December, 2019 but then identified a costing issue which took until February 2020 to sort then COVID - 19 hit
26	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	16/08/2019	19/11/2019	29/10/2019	29/11/2019	06/12/2019	12/12/2019	14/01/2020	Please select	
27	19/NM/0442	262204	An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	13/09/2019	17/12/2019	08/08/2019	17/12/2019	18/12/2019	19/12/2019		Neither	The eligibility for this study is quite restrictive and no eligible patients have been identified. Once Covid-19 happened Sponsor halted the study on 26th March
28	19/YH/0301	268446	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	13/09/2019	12/12/2019	31/10/2019	20/12/2019	23/12/2019	23/12/2019		Sponsor	Study did not become activated until the beginning of March. No patient was identified in early March then the study was suspended by sponsor because of COVID-19
29	19/EM/0220	265213	A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	06/12/2019	06/12/2019	11/09/2019	09/12/2019	11/12/2019	12/12/2019	08/01/2020	Please select	
30	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the non-inferiority of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care	14/11/2019	21/11/2019	26/07/2019	04/12/2019	05/12/2019	05/12/2019	12/12/2019	Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
31	18/SC/0427	220853	The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study.	05/12/2019	05/12/2019	15/10/2018	10/12/2019	11/12/2019	11/12/2019	21/12/2019	Please select	
32	19/NW/0001	253853	IDL-2965 – A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	04/09/2019	04/10/2019	05/03/2019	27/09/2019	10/10/2019	10/10/2019		Neither	The study has two Bronchoscopies one of which is at screening to confirm eligibility and this is quite an invasive procedure and a lot for patients to go through to then be ruled out of the study. No patients were identified locally then the sponsor closed recruitment nationally in July 2020
33	19/SC/0253	264426	Safety, tolerability and pharmacokinetics of single rising intravitreal doses of BI 754132 in patients with geographic atrophy secondary to age-related macular degeneration (open label, non-randomized, uncontrolled).	04/10/2019	18/10/2019	08/07/2019	22/10/2019	24/10/2019	30/10/2019	06/02/2020	Neither	This is a Phase I recruitment study and has been on hold between cohorts for safety analysis prior to dose escalation. Patients are put on waiting list by sponsor until they allocate a place to them for treatment
34	19/YH/0230	264808	A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)	04/12/2019	17/12/2019	05/09/2019	09/01/2020	10/01/2020	10/01/2020		Sponsor	Study did not become activated until the beginning of March. No patient was identified then the study was suspended by sponsor because of COVID-19
35	19/YH/0188	264996	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.	16/12/2019	14/01/2020	07/08/2019	15/01/2020	15/01/2020	15/01/2020	11/02/2020	Please select	
36	19/NE/0312	266862	AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)	24/09/2019	15/01/2020	13/11/2019	15/01/2020	29/01/2020	29/01/2020	11/02/2020	Please select	
37	17/LO/0038	182633	UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	24/09/2019	24/10/2019	10/04/2017	20/01/2020	20/01/2020	22/01/2020		Sponsor	Contracting delays held up the opening of the study initially. Then the study was suspended due to COVID-19
38	19/LO/1336	256748	An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years	15/05/2019	15/01/2020	13/11/2019	20/01/2020	23/01/2020	24/01/2020		Sponsor	Sponsor has had difficulty getting their database ready to recruit and randomise. The research team are still waiting for the green light.
39	18/LO/0486	235388	A randomised controlled trial of Specialist Physiotherapy for Functional Motor Disorder (Physio4FMD)	30/09/2019	18/12/2019	29/03/2018	17/12/2019	10/01/2020	14/01/2020	15/02/2020	Please select	
40	19/ES/0112	268502	Personalised Nutrition in Non-Alcoholic Fatty Liver Disease: Feasibility of a Nutrigenomic Therapeutic Approach	09/07/2019	02/01/2020	10/10/2019	13/01/2020	13/01/2020	13/01/2020	11/02/2020	Please select	
41	19/SC/0311	262176	ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis	21/08/2019	16/01/2020	07/08/2019	17/01/2020	23/01/2020	27/01/2020		Sponsor	Study has just reopened after being suspended by sponsor due to COVID-19

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
42	18/LO/1937	249639	A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	30/01/2020	10/02/2020	01/03/2019	12/02/2020	24/02/2020	24/02/2020	01/07/2020	Neither	This is a very rare patient group, they need to have a rare condition and then they have to fail standard therapy
43	17/EE/0368	213669	STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)	28/01/2019	13/02/2020	10/11/2017	11/02/2020	13/02/2020	13/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
44	19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	28/02/2019	09/01/2020	17/12/2019	23/01/2020	06/02/2020	06/02/2020	10/03/2020	Please select	
45	18/NW/0110	236974	NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadjuvant therapy in ER-positive intermediate recurrence score primary breast cancer	03/10/2019	20/01/2020	12/06/2019	13/02/2020	21/02/2020	21/02/2020		Sponsor	Study was suspended by sponsor due to COVID-19 and has recently re-opened and actively looking for patients
46	19/NE/0317	265622	High Flow Weaning in Preterm Infants: Physiology and Outcomes	20/01/2020	05/02/2020	07/01/2020	06/02/2020	06/02/2020	06/02/2020		Sponsor	Study was suspended by sponsor due to COVID-19 and has recently re-opened and is actively looking for patients
47	18/NE/0264	250542	Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo single masked parallel trial (TRACKER)	11/07/2019	21/01/2020	27/09/2018	03/01/2020	10/02/2020	10/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
48	19/LO/1270	261294	CRAFT: Cerclarge after full dilatation caesarean section; an investigation into the role of previous in labour caesarean section in future preterm birth risk and potential management strategies	16/08/2019	07/02/2020	20/09/2019	17/06/2019	21/02/2020	21/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
49	19/YH/0229	266822	A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)	31/01/2020	21/02/2020	07/09/2019	21/02/2020	25/02/2020	25/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
50	18/YH/0330	236317	A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance	01/10/2019	05/12/2019	29/11/2018	13/02/2020	20/02/2020	20/02/2020		Sponsor	Sponsor made late changes to the PIC agreement, so it had to be reviewed again over the Christmas break. There were a number of conflicting factors with the study which caused delays with sponsor. Sponsor informed site of the early termination of the study in May 2020

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
51	18/EE/0282	249797	AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	23/10/2019	14/01/2020	29/10/2018	16/01/2020	05/02/2020	05/02/2020	27/02/2020	Please select	
52	18/SC/0286	246516	A Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 after a Single Oral Dose and Multiple Ascending Oral Doses in Healthy Subjects and Patients with Primary Mitochondrial Disease	01/11/2019	13/02/2020	24/10/2019	14/02/2020	21/02/2020	21/02/2020		Sponsor	Study was suspended by sponsor due to COVID-19 and has recently re-opened and actively looking for patients
53	19/LO/1116	258919	A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies	14/02/2020	24/02/2020	24/09/2019	25/02/2020	25/02/2020	25/02/2020	03/08/2020	Sponsor	Study was suspended by sponsor due to COVID-19
54	19/NW/0317	262846	A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough	19/02/2020	19/02/2020	12/07/2019	21/02/2020	25/02/2020	25/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
55	17/NW/0581	214739	Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial	28/11/2019	25/02/2020	07/08/2018	27/02/2020	03/03/2020	06/03/2020		Sponsor	Study suspended by sponsor due to COVID-19
56	19/NW/0504	264255	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy	05/02/2020	21/02/2020	09/12/2019	05/03/2020	12/03/2020	12/03/2020	07/07/2020	Sponsor	Study was suspended by sponsor due to COVID-19
57	19/EM/0189	264788	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	05/12/2019	14/02/2020	17/07/2017	14/02/2020	09/03/2020	09/03/2020		Sponsor	Study suspended by sponsor due to COVID-19

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
58	19/LO/0333	259569	A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus (CMV) seropositive recipients (R+) of an allogenic hematopoietic stem cell transplant (HSCT)	05/08/2019	10/02/2020	02/05/2019	02/03/2020	05/03/2020	05/03/2020	17/08/2020	Neither	No patients were seen initially due to COVID-19
59	19/NE/0269	268944	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	27/08/2019	05/02/2020	31/10/2019	25/02/2020	28/02/2020	05/03/2020	06/07/2020	Sponsor	Study was suspended initially by sponsor due to COVID-19
60	19/EM/0264	266058	In younger adults with unstable ankle fractures treated with close contact casting, is ankle function not worse than those treated with surgical intervention? The Fractured Ankle Management Evaluation (FAME) Trial.	17/02/2020	25/02/2020	03/09/2019	26/02/2020	06/03/2020	10/03/2020		Sponsor	Study suspended by sponsor due to COVID-19
61	19/NE/0328	270912	M19-164: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab.	24/10/2019	07/02/2020	19/11/2019	06/03/2020	06/03/2020	06/03/2020		Neither	No patients seen due to COVID-29
62	19/LO/1423	269751	A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS AND YOUNG ADULTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION OR RECURRENT/REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS	24/02/2020	11/03/2020	21/11/2019	06/03/2020	13/03/2020	13/03/2020		Sponsor	Study suspended by sponsor initially due to COVID-19
63	19/WM/0266	266172	Treatment of Hidradenitis Suppurativa Evaluation Study	21/11/2019	07/02/2020	03/10/2019	26/02/2020	03/03/2020	06/03/2020	10/09/2020	Sponsor	Study was suspended initially by sponsor due to COVID-19
64	19/EM/0300	267054	Effectiveness of an image analysing algorithm to diagnose non-melanoma skin cancers compared to gold standard histological determination.	13/01/2020	07/02/2020	17/10/2019	10/03/2020	10/03/2020	13/03/2020		Sponsor	Study suspended intially by sponsor due to COVID-19
65	20/SC/0154	281800	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults	30/03/2020	30/03/2020	26/03/2020	30/03/2020	30/03/2020	30/03/2020	31/03/2020	Please select	
66	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	13/03/2020	13/03/2020	17/03/2020	13/03/2020	25/03/2020	25/03/2020	26/03/2020	Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
67	18/SW/0047	232201	Distal pancreatectomy, minimally invasive or open, for malignancy (DIPLOMA) A pan-European, randomised controlled, multicentre, patient blinded, non-inferiority trial.	21/11/2018	15/01/2020	15/08/2019	16/01/2020	16/01/2020	16/01/2020		Sponsor	Problems with the Green Light from Sponsor caused original delays to recruitment then the site had COVID-19 delays
68	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	25/03/2020	08/04/2020	17/01/2020	08/04/2020	14/04/2020	14/04/2020	18/06/2020	Sponsor	Initials delays with recruitment were caused by sponsor suspending study due to COVID-19
69	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	06/04/2020	07/04/2020	23/07/2018	08/04/2020	14/04/2020	14/04/2020	20/04/2020	Please select	
70	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	23/04/2020	23/04/2020	03/04/2020	23/04/2020	23/04/2020	23/04/2020	29/09/2020	Neither	No patient presented due to the strict criteria eligibility
71	20/SC/0179	281904	A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19	07/05/2020	20/05/2020	04/05/2020	21/05/2020	21/05/2020	21/05/2020	26/05/2020	Please select	
72	20/LO/0279	277975	ReCerf® total hip resurfacing	11/06/2020	11/06/2020	22/04/2020	18/06/2020	22/06/2020	22/06/2020	30/06/2020	Please select	
73	20/SC/0201	282769	ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients	28/05/2020	03/06/2020	28/04/2020	05/06/2020	08/06/2020	08/06/2020	18/06/2020	Please select	
74	20/HRA/2191	283184	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”	10/06/2020	16/06/2020	06/05/2020	18/06/2020	23/06/2020	23/06/2020		Neither	No patients have presented due to the strict criteria eligibility
75	19/NE/0130	237080	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Paediatric and Young Adult Patients with Relapsed or Refractory Malignancies	24/02/2020	10/03/2020	23/07/2019	14/07/2020	14/07/2020	14/07/2020	06/08/2020	Sponsor	Set up was delayed due to COVID-19
76	18/LO/0508	241903	An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients With Haemophilia B	19/02/2020	08/07/2020	15/05/2018	09/07/2020	09/07/2020	09/07/2020	13/07/2020	Please select	
77	20/EE/0135	282213	Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)	22/06/2020	16/07/2020	06/05/2020	17/07/2020	17/07/2020	20/07/2020		Neither	No patient presented due to the strict criteria eligibility
78	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER’S DISEASE	27/05/2020	12/08/2020	20/04/2020	14/08/2020	14/08/2020	17/08/2020		Neither	This study deals with a rare disease no patient has presented to the team
79	19/ES/0126	271121	A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations	03/10/2019	02/03/2020	01/11/2019	05/08/2020	25/08/2020	25/08/2020		Sponsor	Initial delays with set up were due to COVID-19. No eligible patient has been seen since the study was approved

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
80	19/LO/1837	271981	An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors	30/03/2020	16/06/2020	14/01/2020	23/07/2020	12/08/2020	12/08/2020		Neither	Initial delays with set up were due to COVID-19. No eligible patient has been seen since the study was approved. This study deals with a rare disease
81	19/LO/1753	269460	A phase 2, ranodmised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subutaneous injection administered every week in patients with Alport Syndrome	29/06/2020	21/07/2020	13/02/2020	20/07/2020	03/08/2020	03/08/2020	20/08/2020	Please select	
82	17/NW/0649	227917	The ASsessment and Physiotherapy managEment of ataxia in Children following surgical resection of posterior fossa Tumour	11/07/2019	10/03/2020	05/03/2018	04/02/2020	12/08/2020	13/08/2020		Neither	Initial delays were due to COVID-19. Since the study was approved no patients have been identified that are suitable for the study
83	19/NW/0342	264974	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation	17/02/2020	09/03/2020	25/07/2019	16/03/2020	12/08/2020	12/08/2020		Sponsor	Initial delays were caused by COVID-19. Since approval no patient has fitted the strict eligibility criteria
84	17/WA/0155	223941	Primary care Management of lower Urinary tract Symptoms in men: Development and validation of a diagnostic and decision-making aid.	21/01/2020	09/09/2020	23/08/2017	29/09/2020	29/09/2020	29/09/2020		Please select	
85	19/LO/1195	261755	A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment	17/08/2020	15/09/2020	05/12/2019	21/09/2020	28/09/2020	28/09/2020		Please select	
86	19/NE/0215	234453	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	03/10/2019	19/02/2020	07/11/2019	09/07/2020	09/09/2020	30/09/2020		Sponsor	Set up was delayed due to COVID-19

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
87	20/NE/0058	275056	A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)	23/07/2020	21/08/2020	30/04/2020	03/09/2020	14/09/2020	15/09/2020		Please select	
88	19/NE/0357	271261	A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMOR Study	29/11/2019	30/07/2020	06/01/2020	31/08/2020	01/09/2020	01/09/2020		Please select	
89	19/NI/0126	254829	SMALL: A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision	09/03/2020	14/09/2020	15/10/2019	17/09/2020	18/09/2020	25/09/2020		Please select	
90	19/LO/1949	274671	AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	06/08/2020	06/08/2020	17/02/2020	10/09/2020	14/09/2020	15/09/2020	28/09/2020	Please select	
91	19/SC/0107	237804	A phase II trial assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer	04/08/2020	04/08/2020	05/07/2019	18/09/2020	21/09/2020	21/09/2020		Sponsor	Initial delays were due to contracting delays within the sponsor company
92	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	11/06/2020	29/07/2020	20/05/2020	01/09/2020	02/09/2020	02/09/2020		Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments